Breast Cancer

Fulvestrant plus palbociclib after aromatase inhibitor plus palbociclib led to improvements in progression-free survival for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Elacestrant significantly improved progression-free survival in estrogen receptor–positive HER2-negative metastatic breast cancer.

A pooled analysis found that genomic alterations identified through multigene sequencing led to progression-free survival improvements over maintenance chemotherapy for HER2-negative metastatic breast cancer.

Black women with breast cancer had a 3.5-fold higher rate of lymphedema over 24 months compared with White women.

Treatment with tamoxifen for primary breast cancer may result in increased risk of developing subsequent uterine cancer by activating the PI3K pathway.

Experts discuss the use of trastuzumab-deruxtecan (T-DXd) in clinical practice.

Sara A. Hurvitz, MD, briefly describes the treatment landscape for HER2+ breast cancer and the panelists take an in-depth look at the data from the DESTINY-Breast03 trial.

Olaparib, which was granted priority review by the FDA, has been shown to improve invasive disease-free survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.

In another patient case, panelists break down third-line therapy options for someone with HER2+ metastatic breast cancer and lung disease.

Moving to optimal treatment approaches in second-line therapy, experts close out a patient case of HER2+ metastatic breast cancer.

Patients who were given extended 5-year treatment with letrozole plus 2 to 3 years of tamoxifen experienced an improvement in disease-free survival compared with 2 to 3 years of treatment with letrozole.

Breast cancer survivors who are minorities or medically underserved appear to experience a benefit in health-related quality of life after taking part in a community-based physical activity program.

Patients with stage IV breast cancer who received a systemic therapy plus surgery experienced a higher survival benefit than those receiving systemic treatment alone.

Using a patient case to center their discussion, the panel reviews frontline treatment options for HER2+ metastatic breast cancer and the rationale behind selection.

Fielding questions from a live audience, experts discuss the lack of biomarkers in HER2+ metastatic breast cancer and how one might address progression of bone disease.

Attention needs to be paid to the psychosocial needs of patients, especially those with poor health-related quality of life, who have little support, or are single mothers.

A panel of experts reviews clinical trial data in recurrent HER2-positive metastatic breast cancer and discusses impacts on treatment selection.

Panelists provide an overview of the treatment landscape for patients with HER2-positive metastatic breast cancer.

Patients with hormone receptor–positive breast cancer in 3 separate subgroups showed an overall survival benefit when treated with eftilagimod alpha plus paclitaxel compared with the placebo.

Research estimates suggest that the cost of metastatic breast cancer, especially in younger and midlife women, is expected to rise from 2015 through 2030 along with the overall prevalence of cases.

Germline testing for BRCA1/2 mutations in tumor tissue for treatment selection of PARP inhibition in HER2-negative metastatic breast cancer did not show large differences in outcomes compared with blood testing, inferring feasibility of tumor testing.

Findings from a study indicated that non-Hispanic American Indian and Alaskan Native patients with breast cancer were more likely to undergo a mastectomy compared with non-Hispanic White patients.

Patients with hormone receptor–positive, ERBB2-negative advanced breast cancer experienced significant anti-tumor activity when treated with fulvestrant and palbociclib but did not see an improvement in progression-free survival compared with letrozole and palbociclib .

Patients who were treated with extreme hypofractionation after breast conserving surgery saw no increase in ill-treatment effects compared with those receiving moderate hypofractionation.